PEMBROLIZUMAB , BNT113
BNT113-01
Phase 3 small_molecule active
Quick answer
PEMBROLIZUMAB , BNT113 for Unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer is a Phase 3 program (small_molecule) at BioNTech Manufacturing GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BioNTech Manufacturing GmbH
- Indication
- Unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active